115 / 1835
Classical HL in clinical stage I/II without risk factors*
Age 18 - 75
1 x anti-PD-1 antibody
#
20 Gy IS-RT
§
5 x anti-PD-1 antibody
#
20 Gy IS-RT
§
6 x anti-PD-1 antibody
* Risk factors: Large med mass, extranodal lesion, elevated ESR, ≥ 3 nodal areas
#
x mg/kg every 2 weeks
§
IS-RT starts on day 5 after the first infusion on the anti-PD-1 antibody
Phase II trial
RT and anti-PD1 in early favorable cHL